RU2020126574A - Векторы, ускользающие от иммунного надзора, и их применение в генотерапии - Google Patents
Векторы, ускользающие от иммунного надзора, и их применение в генотерапии Download PDFInfo
- Publication number
- RU2020126574A RU2020126574A RU2020126574A RU2020126574A RU2020126574A RU 2020126574 A RU2020126574 A RU 2020126574A RU 2020126574 A RU2020126574 A RU 2020126574A RU 2020126574 A RU2020126574 A RU 2020126574A RU 2020126574 A RU2020126574 A RU 2020126574A
- Authority
- RU
- Russia
- Prior art keywords
- enveloped virus
- virus vector
- vector
- enveloped
- aav
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims 61
- 230000037451 immune surveillance Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 claims 62
- 238000000034 method Methods 0.000 claims 33
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 25
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 25
- 108020004707 nucleic acids Proteins 0.000 claims 25
- 102000039446 nucleic acids Human genes 0.000 claims 25
- 150000007523 nucleic acids Chemical class 0.000 claims 25
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 22
- 108700019146 Transgenes Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 19
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 18
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 18
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 230000001506 immunosuppresive effect Effects 0.000 claims 16
- 230000003612 virological effect Effects 0.000 claims 14
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 13
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 13
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 13
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 239000012528 membrane Substances 0.000 claims 8
- 102100022641 Coagulation factor IX Human genes 0.000 claims 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 7
- 210000001808 exosome Anatomy 0.000 claims 7
- 241000700584 Simplexvirus Species 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 5
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 5
- 208000009292 Hemophilia A Diseases 0.000 claims 5
- 208000009429 hemophilia B Diseases 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 4
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims 4
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims 4
- 208000003571 choroideremia Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000033810 Choroidal dystrophy Diseases 0.000 claims 3
- 241000713666 Lentivirus Species 0.000 claims 3
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 3
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 3
- 108090000697 Myotubularin Proteins 0.000 claims 3
- 102000004128 Myotubularin Human genes 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 239000013607 AAV vector Substances 0.000 claims 2
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 208000024720 Fabry Disease Diseases 0.000 claims 2
- 108010076282 Factor IX Proteins 0.000 claims 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims 2
- 239000000232 Lipid Bilayer Substances 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 2
- 201000011252 Phenylketonuria Diseases 0.000 claims 2
- 102100029740 Poliovirus receptor Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims 2
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 208000005980 beta thalassemia Diseases 0.000 claims 2
- 208000016617 citrullinemia type I Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004222 factor ix Drugs 0.000 claims 2
- 238000010362 genome editing Methods 0.000 claims 2
- 201000004502 glycogen storage disease II Diseases 0.000 claims 2
- 102000057593 human F8 Human genes 0.000 claims 2
- 229960000900 human factor viii Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010048507 poliovirus receptor Proteins 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 1
- 241000649045 Adeno-associated virus 10 Species 0.000 claims 1
- 241000649046 Adeno-associated virus 11 Species 0.000 claims 1
- 241000649047 Adeno-associated virus 12 Species 0.000 claims 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 claims 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 claims 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 claims 1
- 201000011297 Citrullinemia Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 101150026402 DBP gene Proteins 0.000 claims 1
- 108091027757 Deoxyribozyme Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 108010017544 Glucosylceramidase Proteins 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 claims 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims 1
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 claims 1
- 101710106576 NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 1
- -1 RNzyme Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 101150008036 UL29 gene Proteins 0.000 claims 1
- 101150011902 UL52 gene Proteins 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 108700004026 gag Genes Proteins 0.000 claims 1
- 101150098622 gag gene Proteins 0.000 claims 1
- 229960000027 human factor ix Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108010054126 retinoid isomerohydrolase Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
- C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862616167P | 2018-01-11 | 2018-01-11 | |
| US62/616,167 | 2018-01-11 | ||
| US201862768779P | 2018-11-16 | 2018-11-16 | |
| US62/768,779 | 2018-11-16 | ||
| PCT/US2019/013361 WO2019140311A1 (en) | 2018-01-11 | 2019-01-11 | Immuno-evasive vectors and use for gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020126574A true RU2020126574A (ru) | 2022-02-11 |
Family
ID=65444323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020126574A RU2020126574A (ru) | 2018-01-11 | 2019-01-11 | Векторы, ускользающие от иммунного надзора, и их применение в генотерапии |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200338216A1 (https=) |
| EP (1) | EP3737768A1 (https=) |
| JP (2) | JP7406253B2 (https=) |
| KR (1) | KR20200128519A (https=) |
| CN (1) | CN111836896A (https=) |
| AU (1) | AU2019206639A1 (https=) |
| BR (1) | BR112020014093A2 (https=) |
| CA (1) | CA3088897A1 (https=) |
| CL (1) | CL2020001850A1 (https=) |
| IL (1) | IL275951A (https=) |
| MX (1) | MX2020007390A (https=) |
| RU (1) | RU2020126574A (https=) |
| SG (1) | SG11202006298XA (https=) |
| WO (1) | WO2019140311A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4118219A4 (en) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Novel use of aspirin compound in increasing nucleic acid expression |
| US20230355803A1 (en) * | 2020-06-24 | 2023-11-09 | Chameleon Biosciences, Inc. | Extracellular vesicles with immune modulators |
| CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
| WO2023028035A1 (en) * | 2021-08-23 | 2023-03-02 | University Of Florida Research Foundation, Incorporated | Lipid enveloped recombinant aav particles for gene therapy use |
| EP4660308A1 (en) * | 2023-01-31 | 2025-12-10 | Synplogen Co., Ltd. | Helper gene |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8672198A (en) | 1997-07-31 | 1999-02-22 | Chiron Corporation | Method enabling readministration of aav vector via immunosuppression of host |
| WO1999055893A1 (en) | 1998-04-29 | 1999-11-04 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| WO2006138670A2 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| JP4691611B1 (ja) | 2010-01-15 | 2011-06-01 | 富士フイルム株式会社 | 有機電界発光素子 |
| WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
| JP7242180B2 (ja) * | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| CN104887717B (zh) * | 2015-06-04 | 2019-05-31 | 爱康得生物医学技术（苏州）有限公司 | 一种免疫增强试剂 |
| WO2017136764A1 (en) * | 2016-02-05 | 2017-08-10 | The General Hospital Corporation | Hybrid system for efficient gene delivery to cells of the inner ear |
-
2019
- 2019-01-11 BR BR112020014093-7A patent/BR112020014093A2/pt not_active IP Right Cessation
- 2019-01-11 EP EP19705841.5A patent/EP3737768A1/en not_active Withdrawn
- 2019-01-11 AU AU2019206639A patent/AU2019206639A1/en not_active Abandoned
- 2019-01-11 CA CA3088897A patent/CA3088897A1/en active Pending
- 2019-01-11 CN CN201980018276.3A patent/CN111836896A/zh active Pending
- 2019-01-11 RU RU2020126574A patent/RU2020126574A/ru unknown
- 2019-01-11 WO PCT/US2019/013361 patent/WO2019140311A1/en not_active Ceased
- 2019-01-11 JP JP2020538958A patent/JP7406253B2/ja active Active
- 2019-01-11 KR KR1020207022774A patent/KR20200128519A/ko not_active Ceased
- 2019-01-11 SG SG11202006298XA patent/SG11202006298XA/en unknown
- 2019-01-11 US US16/961,500 patent/US20200338216A1/en not_active Abandoned
- 2019-01-11 MX MX2020007390A patent/MX2020007390A/es unknown
-
2020
- 2020-07-09 IL IL275951A patent/IL275951A/en unknown
- 2020-07-10 CL CL2020001850A patent/CL2020001850A1/es unknown
-
2023
- 2023-09-08 JP JP2023146391A patent/JP2023160938A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128519A (ko) | 2020-11-13 |
| US20200338216A1 (en) | 2020-10-29 |
| JP2021510522A (ja) | 2021-04-30 |
| WO2019140311A1 (en) | 2019-07-18 |
| BR112020014093A2 (pt) | 2020-12-01 |
| EP3737768A1 (en) | 2020-11-18 |
| MX2020007390A (es) | 2020-10-14 |
| JP7406253B2 (ja) | 2023-12-27 |
| AU2019206639A1 (en) | 2020-08-20 |
| CA3088897A1 (en) | 2019-07-18 |
| IL275951A (en) | 2020-08-31 |
| JP2023160938A (ja) | 2023-11-02 |
| CL2020001850A1 (es) | 2020-12-04 |
| SG11202006298XA (en) | 2020-07-29 |
| CN111836896A (zh) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sena-Esteves et al. | Introducing genes into mammalian cells: viral vectors | |
| RU2020126574A (ru) | Векторы, ускользающие от иммунного надзора, и их применение в генотерапии | |
| Kay et al. | Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics | |
| Grieger et al. | Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications | |
| Chahal et al. | Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery | |
| JP2021510522A5 (https=) | ||
| KR20200033840A (ko) | 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제 | |
| EP3221456A2 (en) | Genome-modified recombinant adeno-associated virus vectors | |
| US20210299279A1 (en) | Methods and compositions for treating a premature stop codon-mediated disorder | |
| CN115151647B (zh) | Dna扩增方法 | |
| CN121472168A (zh) | 重组修饰腺相关病毒辅助载体及其在提高重组修饰腺相关病毒的包装效率的用途 | |
| KR20240025507A (ko) | 미성숙 종결 코돈-매개 장애를 치료하기 위한 방법 및 조성물 | |
| CA3114108A1 (en) | Methods and compositions for treating a premature stop codon-mediated disorder | |
| US20240101971A1 (en) | Microtubule destabilizer additives to increase recombinant viral vector titers | |
| WO2024079655A1 (en) | Chromatography methods for purification of aav capsids | |
| Nóbrega et al. | Viral vectors for gene therapy | |
| Barzon et al. | Versatility of gene therapy vectors through viruses | |
| EP4051790A1 (en) | Engineered cells for controlled production | |
| Moço | Improving adeno-associated virus serotype 6 production and transduction for gene delivery and CAR T-cell therapy | |
| Martin | Development and Characterisation of HEK293T Cell Expression Systems for Enhanced Production of Recombinant AAV Viral Vectors | |
| Giacca | Methods for gene delivery | |
| WO2025085957A1 (en) | Adeno-associated virus (aav) receptors and uses therefor | |
| Lueptow et al. | Breakthroughs in gene therapy: technological progress, current treatments, and future potential | |
| Jalsic | Generation of cumate/coumermycin inducible HEK293-SF AAV packaging cell lines | |
| Kodippili et al. | Expressing Full-Length Dystrophin Using Adeno-Associated Virus |